VASCULAR ENDOTHELIAL GROWTH FACTOR: FROM VASCULAR PERMEABILITY FACTOR TO A FAMILY OF PLEIOTROPIC GROWTH FACTORS
The earliest known writings on the circulatory system are found in the Ebers Papyrus, an ancient Egyptian medical papyrus dating from the sixteenth century BC, which mentions the connection of the heart to the arteries. It was only in the late 1800s, however, that the idea that specific molecules might control the development of blood vessels has emerged, in particular from studies on tumor angiogenesis, pioneered by Rudolf Virchow. 1 In 1939, Gordon Ide and co-workers 2 observed a massive growth of blood vessels after implanting a tumor in a rabbit's ear and thus postulated the presence of tumor-derived vascular growth factors. More than 30 years later, in a first attempt to isolate a specific pro-angiogenic signal, Folkman et al. 3 identified a soluble 'tumor angiogenic factor' , that was 'mitogenic for endothelial cells and responsible for the formation of new capillaries' . From this evidence, as often happens in science, multiple independent lines of research started and eventually led to the final recognition of the existence of a master regulator of blood vessel formation. On the one hand, Donald Senger and Harold Dvorak in 1983 identified and purified a protein able to induce vascular leakage and named it vascular permeability factor. 4 On the other hand, Ferrara and Henzel 5 isolated and cloned a protein that specifically induced the proliferation of endothelial cells and thus named it vascular endothelial growth factor (VEGF). Further studies showed that VEGF and vascular permeability factor were the same molecule and that these apparently unrelated activities, endothelial cell mitogenesis and induction of vascular permeability, were indeed mediated by the same factor.
In 1992, additional key steps towards a complete understanding of VEGF biology comprised the discovery of the two tyrosine kinase VEGF receptors Flt-1 and KDR, as well as of their different signaling properties. 6, 7 A few years later, Soker et al. in Boston discovered that neuropilin-1, a molecule that was initially characterized for its role in axon guidance, 8 also acted as an additional VEGF receptor, 9 thereby paving the way for further investigation to show that VEGF might not be strictly specific to endothelial cells, but more pleiotropic in nature.
To date, the term VEGF indeed refers to a family of five mammalian factors (VEGF-A, -B, -C, -D and placenta growth factor) and to additional, related proteins of viral (VEGF-E) and snake venom (VEGF-Fs) origin. The proteins encoded by these genes act as homo-or heterodimers through their interaction with three structurally related tyrosine kinase receptors (VEGFR-1/Flt-1, VEGFR-2/Flk-1/KDR and VEGFR-3/Flt-2) expressed on the surface of endothelial cells as well on that of several other cell types. In particular, VEGF-B and placenta growth factor specifically interact with VEGFR-1, VEGF-C and VEGF-D with VEGFR-3, whereas VEGF-A interacts with both VEGFR-1 and VEGFR-2. In addition, the various VEGF family members also exert their variegated functions by interacting with the co-receptors neuropilin-1 and -2, and by the modulation of VEGFR activity through their interaction with other cell surface molecules such as integrins and heparan sulfate proteoglycans. [10] [11] [12] [13] Additional complexity derives from alternative splicing of the VEGF pre-mRNAs. In particular, the VEGF-A gene consists of eight exons that can be alternatively spliced to generate at least seven different protein isoforms, 206, 189, 183, 165, 148, 145 and 121 amino acids. Through their common N-terminal portion, all these proteins can interact with VEGFR-2 and, with an affinity that is 10 times higher, with VEGFR-1. In contrast, bioavailability, biodistribution and the capacity to bind the neuropilin co-receptors depend on the structure of the alternatively spliced C terminus, and in particular on the inclusion of exons 6 and 7. VEGF-A 165 , the prototypic and most abundant VEGF-A isoform, differs from VEGF-A 121 only by the inclusion of exon 7; as a consequence, the former protein binds heparan sulfate proteoglycans in the extracellular matrix and neuropilin-1 co-receptor, whereas the latter does not. 14 Outstanding and broadly comprehensive reviews have been published over the last several years on the properties of VEGF factors and their receptors, their involvement in tumor angiogenesis and on their efficacy in preclinical models of therapeutic angiogenesis. [10] [11] [12] [13] 15 The observation that VEGF-A has acted as a powerful angiogenic factor in small and large animal models of ischemia immediately prompted its utilization in the clinic, also considering the immense medical and socio-economical impact of cardiovascular disorders.
Here, we review the outcome of VEGF-based clinical trials and then summarize the recent information available on the non-angiogenic potential of VEGF family members towards additional clinical application.
CLINICAL USE OF VEGF
An initial attempt to exploit the angiogenic potential of VEGF-A 165 was made by delivering the recombinant protein in patients with coronary heart disease (the Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis, VIVA, trial 16 ). In contrast to the brilliant results obtained by this formulation in various animal models of acute or progressive ischemia, 17 intracoronary protein administration in patients was not effective. Most likely, this negative result stemmed from a combination of reasons, including the very short, half-life of VEGF-A in vivo, insufficient myocardial uptake after coronary infusion and de-sensitization of chronically ischemic tissues to growth factor treatment. It soon became clear that most of these limitations could be overcome by directly delivering the VEGF-A gene, instead of the protein, to the ischemic tissues.
Gene therapy clinical experimentation (Table 1) , originally championed by Isner 18 and supported by experiments performed in both small and large animal models of myocardial and limb ischemia, began in the mid-1990s, by identifying patients with peripheral artery disease (PAD) who had exhausted all conventional options for revascularization. 19 Treatment consisted in the injection of a plasmid coding for VEGF-A 165 . The success of this treatment was evaluated by angiography and nuclear magnetic resonance, revealing the formation of new collateral vessels and a significant perfusion improvement in the VEGF-treated group. 20, 21 The only reported, major side effect was the occurrence of a remarkable edema of the leg, probably due to the potent permeabilizing activity of VEGF. 22 A series of over 20 clinical trials followed in the late 1990s and early 2000s, entailing the injection of naked plasmid DNA encoding VEGF to the myocardium of patients with severe coronary artery disease (CAD) not amenable to surgical revascularization either through a mini left anterior thoracotomy [23] [24] [25] [26] [27] [28] or by a transendocardial approach using a NOGA catheter. 29 Even more recently, an open-label, uncontrolled Phase I trial with a VEGF-A 165 plasmid (the GENESIS I trial) was carried out in Argentina by direct intramyocardial injection in 10 patients. 30 When considered collectively, the results of these experimentations were, overall, indicative of functional improvement in myocardial perfusion and cardiac function, at least at early time points after treatment.
The outcome of these studies, however, should be interpreted with caution, considering their uncontrolled, open-label design and the significant sham or placebo effect observed by any intervention in patients with CAD. Indeed, the initial enthusiasm of the early studies was immediately tempered by the less successful outcome of more recent, double-blind, randomized, placebo-controlled studies. In particular, the first of these studies, the EUROINJECT-ONE trial, failed to show any significant difference in perfusion compared with placebo upon intramyocardial injection of a plasmid encoding VEGF-A 165 , using the NOGA electromagnetic mapping catheter in 80 no-option patients with severe, stable, ischemic heart disease, 31, 32 despite improvement in regional wall motion in the injected areas. The negative results in terms of perfusion were subsequently also duplicated in the NOTHERN trial, in which a fourfold higher dose of plasmid DNA expressing the VEGF-A 165 cDNA or placebo were delivered to the myocardium using the NOGA system in 93 patients with chronic myocardial ischemia for whom standard revascularization procedures were not suitable. 33 Two additional studies attempted to increase VEGF plasmid activity. The first was a small, placebo-controlled trial in Denmark in which patients with severe chronic CAD and no option for revascularization received intramyocardial injections of a VEGF-A 165 plasmid, followed 1 week later by subcutaneous granulocyte-colony-stimulating factor, with the purpose to mobilize hypothetical angiogenic precursor cells from the bone marrow. After 3 months, there were no improvements in myocardial perfusion in the treated patients compared with patients injected with plasmid alone or placebo; accordingly, clinical symptoms also remained unchanged. 34 Another study, the VIF-CAD trial performed in Poland, explored the efficacy of a bicistronic plasmid expressing the VEGF-A 165 cDNA in addition to the fibroblast growth factor-2 cDNA. The trial entailed NOGA-mediated injection into the left ventricular wall of the angiogenic plasmid (33 patients) or placebo (19 patients). Again in this study, no increase in cardiac perfusion was observed in the treated patients, despite marginal, clinical benefit. 35 Finally, a double-blind, placebo-controlled study entailing intramuscular injection of a VEGF-A 165 plasmid to patients with peripheral arterial disease also failed to meet its primary end point (amputation), despite showing objective (reduction of skin ulcers) and subjective (decreased pain) improvements in the treated patients. 36 To improve efficacy of therapeutic angiogenesis based on the VEGF-A gene for patients with PAD or CAD, an innovative possibility, alternative to angiogenic factor cDNA delivery, is to activate expression of the endogenous gene using zinc-finger proteins (ZFP) targeting transcriptional activators to the gene promoter. This approach, which has the advantage of preserving a more physiological VEGF isoform production, was originally demonstrated using a ZFP fused to either VP16 or nuclear factor-kB p65 and targeting the accessible regions of the VEGF-A promoter. 37 One selected ZFP-p65 fusion product was later shown to be effective in vivo in various animal models. [38] [39] [40] Two Phase I studies have positively evaluated this ZFP (named EW-A-401) for safety in humans (http://clinicaltrials.gov/ct2/ show/NCT00080392).
Irrespective of the therapeutic gene involved, plasmid DNA delivery is simple and not fraught with major safety concerns; however, the efficiency of naked DNA uptake by muscle and cardiac cells, even if higher than that occurring in most other cell types, is still very poor. Even by injecting a hundred micrograms or milligrams of plasmid DNA, the proportion internalized by the cells remains at orders of magnitude lower than those obtained using viral vectors. In addition, most preclinical investigations have revealed that measurable levels of gene expression are maintained only for the first couple of weeks after injection, a condition that might not be sufficient to exert an angiogenic stimulus able to generate a stable neovasculature. 41 Taken together, these limitations might ultimately explain the discouraging results of most of the above-described trials, as well as the recent negative outcome of the large, Phase III, TAMARIS Trial, which failed to show the efficacy of a plasmid expressing fibroblast growth factor-1 in patients with PAD. 42 A manner to improve dramatically efficiency of gene delivery is the use of viral vectors. A series of clinical trials performed at the end of the 1990s took advantage of the capacity of adenoviral vectors to transduce cardiomyocytes and skeletal muscle fibers at high efficiency and to express high levels of the proteins encoded by their genomes, including transgenes of interest.
The first vector to be used clinically was a first-generation adenoviral vector expressing the VEGF-A 121 cDNA under the control of the CMV enhancer/promoter, named Ad GV VEGF121.10NH (commercial name: BIOBYPASS). After successful completion of a Phase I clinical trial, 43, 44 the vector was used in the RAVE trial, which assessed the efficacy of the intramuscular injection to the lower extremities of 105 subjects with unilateral peripheral artery obstructive disease. 45 This study showed that a single unilateral intramuscular administration of the vector was not associated with improved exercise performance or quality of life, and did not support further experimentation. 46 The same vector expressing VEGF-A 121 was also tested in two different Phase I trials in patients with CAD, entailing direct intramyocardial injection during coronary bypass artery grafting. 47 In total, 48 The same AdVEGF 121 vector was next used in two studies in which the preparation was delivered to the myocardium by trans-endocardial delivery using the NOGA system. After a Phase I, pilot, safety study, 49 this route of administration was at the basis of a multicenter, randomized, double-blind, placebo-controlled trial performed in Denmark, Israel and the United Kingdom (the NOVA trial). However, after 17 patients were enrolled, the trial was prematurely terminated owing to a sponsoring company's portfolio decision. In any case, no difference was detected in the patients injected with the vector compared with controls as far as exercise capacity, time to ischemic threshold or myocardial perfusion were concerned. 50 Two trials have assessed the efficacy of an adenovirus expressing VEGF-A 165 compared with a plasmid expressing the same gene delivered as a liposome formulation. These were randomized, blinded and placebo-controlled trials in patients with either PAD upon intra-arterial injection after angioplasty (54 patients 51 ) or with CAD after primary coronary intervention (103 patients; the KAT trial 52 ). Both adenovirus and plasmid formulations were reported to improve the vascular density of the treated limbs 3 months after therapy and to enhance myocardial perfusion in the coronary heart disease patients 6 months after therapy. Follow-up studies performed at 8 and 10 years after gene therapy in the peripheral and coronary ischemia studies, respectively, however indicated that there were no significant differences in mortality or incidence of major adverse events between the treatment groups. 53, 54 A first-generation adenoviral vector is also at the basis of a recently initiated, gene therapy angiogenesis trial aimed at delivering VEGF-D to the ischemic myocardium. In particular, this Phase I, singleblinded, placebo-controlled study entails NOGA-mediated transendocardial injection of escalating doses of vector to patients with coronary heart disease with no other therapeutic options (trial KAT301; http://clinicaltrials.gov/show/NCT01002430). The proteolytically processed, mature form of VEGF-D (VEGFDDNDC) binds VEGFR-2 and possesses angiogenic activity similar to VEGF-A 165 , but was reported to promote more uniform and dispersed angiogenesis, probably as a consequence of its more diffusible nature. 55 An adenoviral vector expressing VEGF-D was also at the basis of a Phase III, randomized, multicenter, double-bind trial aimed at preventing stenosis at the graft-vein anastomosis site in dialysis patients (the AdV-VANTAGE trial), based on findings of a previous open-label, Phase IIb study. 56 Sustained and adequate vascular access in patients with renal failure on hemodialysis is provided by surgical placement of a synthetic graft. This graft, however, is often complicated by the development of smooth muscle cell neointimal hyperplasia in the proximity of the graft-vein anastomosis. As VEGF-D was shown to prevent stenosis and thrombosis in this setting-an effect apparently distinct from its angiogenic activity 55 -the trial was aimed at delivering these factors using a first-generation adenoviral vector injected into a collagen collar around the anastomosis (http://clinicaltrials.gov/ ct2/show/NCT00895479). This study, however, was terminated prematurely in 2010, again due to strategic reasons on the part of the sponsoring company.
First-generation adenoviral vectors are fraught with well-established, inflammatory and immunogenic potential, which, de facto, raises safety concerns and limits temporal expression of the transgene. 57 In contrast, a vector system that currently appears very suitable for gene therapy of cardiovascular disorders is that based on AAV. These vectors display a number of appealing features for gene transfer to the heart and the skeletal muscle, including a lack of relevant immunogenicity, the absence of an inflammatory response at the site of injection, the possibility of obtaining relatively pure vector preparations at high titers and the capacity to transduce cells at high multiplicity of infection, which allows mixing of different preparations and thus therapy with gene combinations. [58] [59] [60] In addition, these vectors show a still only partially explained tropism for postmitotic tissues, such as muscle cells and cardiomyocytes, 61 where they drive expression of the therapeutic gene for indefinite periods of time. Given these features, it might be reasonably expected that these vectors will play a central role in clinical cardiovascular gene therapy experimentation in the near future.
VEGF BEYOND THERAPEUTIC ANGIOGENESIS
Parallel to the attempts made to exploit the angiogenic potential of VEGF in the clinic, substantial evidence has emerged to support the pleiotropic activity of the various VEGF family members. Consistent with the widespread expression of VEGF receptors, various VEGFs have been shown to affect an ever-growing list of non-endothelial cell types derived from all three embryonic lineages and to play a major role in the physiological homeostasis of various organs and tissues.
In the bone marrow, both VEGF-A and placenta growth factor exert an essential role, with the former being responsible for hematopoietic cell self-renewal, 62, 63 whereas the latter affect monocyte chemotaxis and activation. 64 In the liver, hepatic stellate cells, the key fibrogenic mesenchymal element in the organ, express both VEGF-A and VEGFRs, and VEGF signaling was shown to promote regeneration after hepatectomy, as well as to control hepatic wound healing and pathological fibrogenesis. 65 In the bone, besides the fundamental role of neovascularization during endochondral bone formation and growth, VEGF-A also controls the proper reabsorption of hypertrophic cartilage and osteoblast maturation. 66, 67 Finally, in the kidney, renal homeostasis also depends on the activity of VEGF, as its conditional inactivation in glomerular podocytes results in nephron malformation and nephrotic syndrome. 68 In addition, a soluble form of VEGFR1 was recently shown to be involved in the pathogenesis of pre-eclampsia. 69 Recently, several reports in mice and rats have shown a direct link between the vascular and the nervous system, with VEGF-A being an important hinge molecule. In retrospect, this should not be surprising, as VEGF and its receptors first appeared in evolution in the central nervous system in species such as the worm and fruit fly, which lack a well-developed vascular system. 70 Apart from its role during the development of the nervous system, VEGF-A has direct effects on various neural cell types, being able to stimulate axonal outgrowth in explant cultures of superior cervical and dorsal root ganglia, 71 and to exert neurotrophic and antiapoptotic activities on various neuronal populations in vitro and in vivo. [72] [73] [74] Consistent with these findings, the first clinical application of VEGF-A in the neurological field dates 10 years back, when it was originally proposed that the factor might successfully treat diabetic neuropathy. 75 On the basis of that evidence, a Phase I/II, single-site, dose-escalating, double-blind, placebo-controlled study evaluated the safety and impact of intramuscular VEGF-A 165 plasmid injection on sensory neuropathy in patients with diabetes. 76 The results of this study showed improved symptoms in the patients treated with VEGF-A, although more objective parameters, such as nerve conduction, resulted unchanged. 77 Another Phase II trial for diabetic neuropathy has taken advantage of the same ZFP activating VEGF-A gene expression described above, under a formulation known as SB-509 (http://clinicaltrials.gov). At the end of 2011, however, this trial was discontinued as it failed to meet its end points (http://www.sangamo.com/pipeline/sb-509.html). Finally, again in the neurological field, recent experiments in animal models of amyotrophic lateral sclerosis have shown that the delivery of VEGF, either as a recombinant protein or as a gene, significantly delayed disease onset and prolonged animal survival. 78 These results have prompted the utilization of the same VEGF-A-activating ZFP also for the treatment of amyotrophic lateral sclerosis (http://clinicaltrials.gov/ ct2/show/NCT00748501).
The different types of muscular cells all respond to VEGF stimulation. On vascular smooth muscle cells, VEGF-A induces cell migration through the activation of VEGFR-2 79 and exerts a key function in the control of peripheral resistance arteries by autonomic nerves. 80 In the skeletal muscle, delivery of VEGF-A significantly improves the myogenic repair process following muscle injury via direct effects on both myogenic precursor cells and mature muscle fibers. 81, 82 Of particular relevance, both VEGF-A and VEGF-B have been implied in the maintenance of physiological homeostasis in the heart, which depends strictly upon the interplay between different cell types. Indeed, cardiomyocytes represent less than a third of the total number of cells in the heart, which is also composed of smooth muscle and endothelial cells of the coronary vasculature and the endocardium, fibroblasts, mast cells, immune cells and, possibly, by pluripotent cardiac stem cells. These cell populations do not work in isolation, but interact physically and functionally in the so-called 'cardiovascular unit' . Interestingly, VEGF members seem able to exert positive effects on most components of the cardiovascular unit (Figure 1 ). Consistent with its potent angiogenic activity, VEGF-A actively performs on both endothelial and smooth muscle cells of the cardiac vasculature, thereby controlling the development of the coronary vessels during development, 83 and inducing a potent angiogenic response after cardiac ischemia in adult organisms. [84] [85] [86] In particular, the arteriogenic properties of the VEGF-A 165 isoform Figure 1 Multiple effects of VEGF family members at the cardiovascular unit. By directly acting on multiple cell types at the cardiovascular unit (endothelial cells, smooth muscle cells, cardiomyocytes, cardiac fibroblasts, bone marrow-derived cells and, possibly, cardiac progenitor cells), the various VEGF family members are expected to act as new therapeutic genes for a variety of cardiac diseases.
VEGF gene therapy M Giacca and S Zacchigna seem to depend, at least in part, on the recruitment of a population of bone marrow-derived mononuclear cells, which in turn act in a paracrine manner to engage smooth muscle cells and pericytes around the growing vessels. 87 Interestingly, VEGF-B also appears to be a coronary growth factor, supporting heart neovascularization, at least in some species. 88 Beside angiogenesis, the same two VEGF family members, VEGF-A and VEGF-B, act directly on cardiomyocytes. Indeed, cardiac myocytes synthesize and secrete VEGF-A in response to hypoxia in vitro and express both VEGFR-2 and VEGFR-1, which become phosphorylated on tyrosines after VEGF stimulation. 86, 89 In particular, VEGFR-1 engagement by both VEGF members results in the direct protection of cardiomyocytes from apoptosis, in the upregulation of genes driving a compensatory, hypertrophic response, in a profound alteration of cardiomyocyte metabolism with lipid and glycogen accumulation 88 and in the attenuation of left ventricle pathological remodeling. 86, 90 Moreover, VEGF-A acting via phospholipase Cg1 imposes a positive ionotropic effect on ventricular cardiomyocytes, thus providing an auto/paracrine mechanism by which the heart controls the strength of the heartbeat during the physiological adaptation response to pressure overload. 91 Besides cardiomyocytes, cardiac myofibroblasts also represent key cellular components during heart development and disease. Interestingly, these cells also express all the main VEGF-A isoforms, as well as their main receptors KDR and Flt-1, 92 and undergo a proliferative response following VEGF stimulation. However, the exact functional effect of VEGF signaling on cardiac myofibroblasts in vivo still remains to be elucidated. Finally, recent evidence indicates that VEGF-A also affects resident adult cardiac stem cells and mediates their recruitment to ischemic areas via the activation of the SDF1/CXCR-4 axis, eventually leading to an improved cardiac repair after myocardial infarction. 93 Overall, these new insights may have several clinical implications. On the one hand, they significantly broaden the diagnostic and therapeutic spectrum of these growth factors. Of relevance in this context, both VEGF-A and VEGF-B may become promising, new tools for treating a variety of cardiac disorders. On the other hand, this pleiotropic nature warrants caution for unwanted, non-vascular toxicity upon administration of VEGF-based gene therapies, 94 or undesirable blocking of non-vascular functions in the context of antiangiogenic therapy, including induction of cardiotoxicity, nephropathy or neurodegeneration.
